These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 17601629)

  • 21. Nanosizing techniques for improving bioavailability of drugs.
    Al-Kassas R; Bansal M; Shaw J
    J Control Release; 2017 Aug; 260():202-212. PubMed ID: 28603030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review: Pharmaceutical and Pharmacokinetic Aspect of Nanocrystalline Suspensions.
    Shah DA; Murdande SB; Dave RH
    J Pharm Sci; 2016 Jan; 105(1):10-24. PubMed ID: 26580860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [On the development of oral preparations of the combination sulfamoxole/trimethoprim (CN 3123) (author's transl)].
    Dechow HJ; Dölcher D; Hübner G; Kim S; Lämmerhirt K; Pich CH; Schmidt-Böthelt E
    Arzneimittelforschung; 1976; 26(42):596-613. PubMed ID: 947320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro methods to assess drug precipitation.
    Dai WG
    Int J Pharm; 2010 Jun; 393(1-2):1-16. PubMed ID: 20347943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size.
    Sinha B; Müller RH; Möschwitzer JP
    Int J Pharm; 2013 Aug; 453(1):126-41. PubMed ID: 23333709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds.
    Kesisoglou F; Mitra A
    AAPS J; 2012 Dec; 14(4):677-87. PubMed ID: 22736294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug nanocrystals - Versatile option for formulation of poorly soluble materials.
    Peltonen L; Hirvonen J
    Int J Pharm; 2018 Feb; 537(1-2):73-83. PubMed ID: 29262301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
    Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
    Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
    Pouton CW
    Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an oral rutin nanocrystal formulation.
    Mauludin R; Müller RH; Keck CM
    Int J Pharm; 2009 Mar; 370(1-2):202-9. PubMed ID: 19114097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of drug delivery technologies in lead candidate selection and optimization.
    Chaubal MV
    Drug Discov Today; 2004 Jul; 9(14):603-9. PubMed ID: 15239979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug nanoparticles: formulating poorly water-soluble compounds.
    Merisko-Liversidge EM; Liversidge GG
    Toxicol Pathol; 2008 Jan; 36(1):43-8. PubMed ID: 18337220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laser diffraction and image analysis as a supportive analytical tool in the pharmaceutical development of immediate release direct compression formulations.
    Tinke AP; Vanhoutte K; Vanhoutte F; De Smet M; De Winter H
    Int J Pharm; 2005 Jun; 297(1-2):80-8. PubMed ID: 15907597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melt extrusion with poorly soluble drugs.
    Shah S; Maddineni S; Lu J; Repka MA
    Int J Pharm; 2013 Aug; 453(1):233-52. PubMed ID: 23178213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. State of the Art of Pharmaceutical Solid Forms: from Crystal Property Issues to Nanocrystals Formulation.
    Couillaud BM; Espeau P; Mignet N; Corvis Y
    ChemMedChem; 2019 Jan; 14(1):8-23. PubMed ID: 30457705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Industrial perspective in ocular drug delivery.
    Ali Y; Lehmussaari K
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1258-68. PubMed ID: 17079049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease.
    Pertuit D; Moulari B; Betz T; Nadaradjane A; Neumann D; Ismaïli L; Refouvelet B; Pellequer Y; Lamprecht A
    J Control Release; 2007 Nov; 123(3):211-8. PubMed ID: 17889397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical methods for dissolution testing of nanosized drugs.
    Jünemann D; Dressman J
    J Pharm Pharmacol; 2012 Jul; 64(7):931-43. PubMed ID: 22686341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.